SEC Form 4 · accession 0001213900-17-010402
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Bacha
Officer — CEO · Director
Period of report
Oct 6, 2017
Accepted (ET)
Oct 10, 2017 · 8:10 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 6, 2017 | P | 7,550 | $0.87 | A | 61,247 | D | |
| Common Stock | Oct 6, 2017 | P | 2,450 | $0.88 | A | 63,697 | D |
Table II — derivative securities
No Table II lines on this filing.